Articles |
From Pennington Biomedical Research Center, Baton Rouge, La (M.L.); the Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY (H.N.G., R. Ramakrishnan); the Nutrition Department, Pennsylvania State University, University Park (P.M.K.-E., J.D.); the Division of Epidemiology, University of Minnesota School of Public Health, Minneapolis (P.J.E.); the Department of Biostatistics, Collaborative Studies Coordinating Center, The University of North Carolina at Chapel Hill (P.W.S.); the Division of Heart and Vascular Diseases, NHLBI, National Institutes of Health, Bethesda, Md (A.E., D.J.G.); the Research Institute, Mary Imogene Bassett Hospital, Cooperstown, NY (T.A.P., R. Reed); and the Department of Physiology, Louisiana State University Medical Center, New Orleans (P.S.R.).
Correspondence to Michael Lefevre, Pennington Biomedical Research Center, 6400 Perkins Rd, Baton Rouge, LA 70808-4124. E-mail lefevrm{at}mhs.pbrc.edu
| Abstract |
|---|
|
|
|---|
Key Words: dietary saturated fat step 1 diet apoE genotype
| Introduction |
|---|
|
|
|---|
The apoE gene is a likely candidate for the study of diet-gene
interactions because this apolipoprotein plays a pivotal role in lipid
and lipoprotein metabolism. ApoE is a structural component
of both chylomicron and VLDL remnants and is thought to mediate their
binding and uptake by both the LDL receptor and the LDL
receptor-related protein.32 33 Three common genetic
variants for apoE have been described:
2 (112cys,
158cys);
3 (112cys, 158arg); and
4 (112arg, 158arg).34 From
cross-sectional studies, the resulting six genotypes may
account for 7% of the population variance in total and LDL
cholesterol levels.35 Relative to the common
3 allele, normal individuals carrying the
2 allele have
lower LDL cholesterol levels, while those carrying the
4
allele have higher LDL cholesterol levels.36
Differences in LDL receptor affinity,37 distribution of
apoE across lipoprotein subclasses,38 absorption of
dietary cholesterol,39 and/or
cholesterol synthesis31 40 associated with
each of the alleles may underlie the observed differences in plasma
and LDL cholesterol levels.
Numerous studies have also shown that apoE genotype can
influence the magnitude of total and LDL cholesterol
response to changes in dietary cholesterol
alone,26 28 changes in dietary fat composition
alone,25 or combined changes in dietary
cholesterol and dietary fat
composition.6 9 14 15 16 31 In these studies, carriers of the
4 allele demonstrated a greater lipid response to dietary
changes than individuals not possessing the
4 allele. However,
an almost equal number of studies5 17 18 19 20 21 22 23 24 27 29 30 have
failed to find any association between apoE genotype and lipid
response.
The DELTA study (Dietary Effects on Lipoproteins and Thrombogenic Activity) is the first well-controlled diet study to use a multicenter approach to examine the impact of changes in dietary fat on risk factors for atherosclerotic cardiovascular disease. A key feature of the DELTA study is that the relatively large study population allows for meaningful comparisons of subpopulation diet responses. In the present report, we determined the lipid response to isocaloric replacement of dietary saturated fat with carbohydrate at constant dietary cholesterol levels in individuals with different apoE genotypes.
| Methods |
|---|
|
|
|---|
Diets and Protocol
Three diets, differing in total and saturated fat, were studied:
an AAD that provided 34.3% of calories from fat with 15.0% saturated,
12.8% monounsaturated, and 6.5% polyunsaturated;
an AHA Step 1 diet providing 28.6% of calories from fat with 9.0%
saturated, 12.9% monounsaturated, and 6.7%
polyunsaturated; and a Low-Sat diet providing 25.3% of calories as
fat, with 6.1% saturated, 12.4% monounsaturated,
and 6.7% polyunsaturated. All of the diets provided approximately 15%
of calories as protein with the remainder of the diet as carbohydrate.
Dietary cholesterol averaged 275 mg/d in all three
diets.
The three diets were provided to the individual subjects in a randomized, double-blind, three-way crossover design, with each diet period lasting 8 weeks. Breaks of 4 to 6 weeks were provided between each diet period. With the exception of an optionally self-selected Saturday evening meal that was required to meet the National Cholesterol Education Program Step 1 dietary recommendations,42 all diets consumed by the subjects were prepared by the research centers. Subjects were required to eat two meals a day on site during the weekdays. The remaining weekday meal, snacks, and weekend meals were packaged for consumption off site. The design, validation, preparation, presentation, and monitoring of these diets are described in detail elsewhere.43
Laboratory Analysis
Twelve-hour fasting blood samples were obtained once per week
during the last 4 weeks of each diet period. Standardized blood
sampling and processing procedures were validated and used at all four
research centers. Plasma and serum were isolated by
centrifugation for 30 000gxmin
immediately after collection. Aliquots of each were stored in cryovials
at -80°C until the end of the study, when all samples were assayed.
Buffy coats were removed for DNA analysis and separately frozen
in cryovials at -80°C.
Each research center determined serum concentrations of total cholesterol, LDL cholesterol, HDL cholesterol, and TGs using enzymatic assays. HDL cholesterol was determined after precipitation of apoB-containing lipoproteins with dextran-sulfate (molecular weight 50 000). All laboratories participated in a special lipid standardization protocol administered by the Centers for Disease Control (CDC). Briefly, pooled serums for total cholesterol and HDL cholesterol were sent to each research center by CDC; results were analyzed by CDC. The within-laboratory coefficients of variation were <1.9% for cholesterol and <2.5% for HDL cholesterol. The interlaboratory coefficients of variation were <2.8% for cholesterol and <6.1% for HDL cholesterol. The demonstrated precision and accuracy of each research center laboratory were adequate to allow the data to be combined.
ApoA-I and apoB were determined by rate immunonephelometry (Beckman Array). The coefficients of variation of the apolipoprotein assays were less than 6%. ApoE genotype was determined by polymerase chain reaction amplification of leukocyte DNA followed by Hha I digestion and product characterization essentially as described by Hixson and Vernier.44 All apolipoprotein assays and apoE genotypings were conducted at a single laboratory (Mary Imogene Bassett Research Institute, Cooperstown, NY).
Statistical Analyses
Individuals were assigned to one of three apoE subgroups on the
basis of their apoE genotype: E2 (E2/2, E2/3, E2/4); E3 (E3/3);
or E4 (E3/4, E4/4). To compare apoE genotype subgroups with
respect to responsiveness to experimental reductions in dietary
saturated fat, statistical analyses were performed for each of
six response variables: total cholesterol, LDL
cholesterol, HDL cholesterol, TGs (natural log
scale), apoB, and apoA-I. For each of these variables, the primary
a priori hypotheses tested were (1) each genotype subgroup
is responsive to dietary changes and (2) some of the genotype
subgroups are more responsive than others.
Well-established procedures45 46 47 48 49 50 for estimation and testing were applied to take full advantage of all of the longitudinal data. The linear statistical model, the set of primary hypotheses, the strategy for controlling type I error, and the estimation procedures were all specified a priori. The mean of the conditional distribution of assay values was assumed to be a linear function of six categorical factors (number of levels shown in parentheses): apoE genotype (3), diet (3), race (2), gender-age group (4), research center (4), feeding period (3), and interaction of diet with genotype, race, gender-age group and research center. The variance of the conditional distribution of assay values was assumed to be constant across all factor levels and occasions. The correlation between any two of an individual's assay values was assumed to be larger for same-diet pairs, smaller for different-diet pairs, but otherwise invariant. This model was represented and interpreted as a components-of-variance model, with the residual variance being the sum of three components: interindividual variance of the individuals' overall mean levels ("subject"), interindividual variance of the individuals' diet-specific mean levels ("diet by subject"), and intraindividual variation ("within-subject"). The necessary statistical computations for estimation and testing were performed using the mixed-model procedure of the SAS software system.45
Secondary analyses were used to determine the sensitivity of the main results to perturbations of the modeling assumptions and to address secondary research questions. For example, to address secondary questions about the roles of BMI, age, and gender, auxiliary analyses were performed. To address secondary questions about variance and covariance, several kinds of alternative covariance structures were also examined. Also, the data were examined for evidence of any departures from the modeling assumptions.
On the basis of estimates of variance components, power computations were performed to verify previous perceptions about the magnitude of statistical power available in this study and similar studies.
| Results |
|---|
|
|
|---|
|
Baseline Characteristics and Plasma Lipids on AAD
Baseline characteristics of subjects in each genotype
group are shown in Table 2
. Age did not
differ substantially among the genotype groups. While not
statistically significant, there were proportionately more males in the
E3 group (49%) than in the other two groups (E2, 36%; E4, 40%) and
the average BMI for the E2 group tended to be higher than for either
the E3 or E4 groups. Total cholesterol, LDL
cholesterol, and apoB, measured while subjects were
consuming the AAD, increased across the genotype groups in the
expected order: E2<E3<E4. However, none of these differences was
statistically significant, even after adjustment for age, gender, and
race. HDL cholesterol and apoA-I were lower in the E4 group
relative to the E3 group. For apoA-I, this difference was significant
(P=.006). No significant difference across genotype
groups was identified for TGs.
|
ApoE Genotype and Diet Response
In Fig 1
, we show the interaction
between apoE genotype groups and plasma lipid response to the
lower fat diets. Data are presented as the mean difference
between the AAD and the Step 1 or Low-Sat diets. Consumption of either
the Step 1 diet or the Low-Sat diet resulted in statistically
significant reductions (P<.001 as indicated by asterisks)
in both total and LDL cholesterol levels within each apoE
genotype group. For example, in response to the Step 1 diet,
the E4, E3, and E2 groups experienced LDL reductions of 6%, 7%, and
11%, respectively. There was no substantial evidence that the
genotype groups varied in responsiveness; the diet by
genotype interaction was not significant for either total
cholesterol (P=.77) or LDL
cholesterol (P=.15) across all diets. While
there was the appearance of a trend across the apoE genotype
groups with the response to the Step 1 diet, this trend was in a
direction opposite that previously reported for apoE (ie, lower
relative response with apoE4 rather than greater response) and was not
maintained with the Low-Sat diet.
|
Similar results were obtained with both the HDL cholesterol
and TG responses (Fig 1
). With the exception of the E2 group in the
Step 1AAD comparison, HDL cholesterol fell significantly
in each apoE genotype as dietary saturated fat was replaced by
carbohydrate. Increases in TG levels were significant in the E3 and E4
groups in the Step 1AAD comparison and in the E4 group in the
Low-SatAAD comparison. As with total cholesterol and LDL
cholesterol, there was no evidence of a significant effect
of apoE genotype group on the magnitude of either the HDL
cholesterol (P=.80) or TG (P=.54)
response.
Fig 2
shows the apolipoprotein responses
by apoE genotype group. Reductions in saturated fat
significantly reduced apoA-I levels in all apoE genotype groups
with the exception of the E2 group in the Step 1AAD comparison. As
with HDL cholesterol, there was no evidence of a diet by
genotype interaction (P=.14). Significant reductions
in apoB in the apoE genotype groups were observed in the E3
group in the Step 1AAD comparison and in all three genotype
groups in the Low-SatAAD comparison. Despite the apparent large
differences in apoB response between the genotype groups, they
were not statistically significant (P=.44). Furthermore,
like LDL cholesterol, it was the E2 group, not the E4
group, that showed the greatest apparent reductions in apoB with the
Step 1 diet.
|
A recent study by Lopez-Miranda et al14 suggested that the
apoE genotype effect on diet response may be more pronounced in
males than in females. Since our study population was 55% females, the
apoE genotype effect on LDL cholesterol response
was examined separately in males and females (Fig 3
). In both groups, the LDL
cholesterol response to diet was very similar when examined
across apoE genotype groups. The formal test of the
hypothesized diet by genotype by gender interaction was not
significant (P=.75).
|
In addition to gender, we also examined the diet by genotype
interactions as a function of race. In Fig 4
, results are shown for LDL
cholesterol response by genotype for both blacks
and nonblacks (predominantly whites). Again, for both racial groups,
the LDL cholesterol response was similar across
genotype, with no significant diet by apoE genotype
interaction in either racial group (P=.60).
|
Secondary Statistical Analyses
We examined the robustness of our negative findings by considering
a number of auxiliary statistical models. In previous studies, it has
been suggested that age, BMI, and baseline lipid levels (ie, levels on
AAD) may influence response to diet. To remove the potential
confounding effects, if any, of these parameters, BMI and
age and their interactions with diet were initially entered into our
previous statistical model (Table 3
,
statistical model 2). Age was predictive of total
cholesterol (P=.0007), LDL
cholesterol (P=.0004), and TG
(P=.044) levels, independent of diet treatment, while BMI
was predictive of total cholesterol (P=.018) and
LDL cholesterol (P=.037). However, neither age
nor BMI were predictive of the magnitude of diet response for any of
the measured end points. Furthermore, inclusion of BMI, age, and their
diet interaction terms in the model did not alter the negative findings
regarding apoE genotype and diet response.
|
Inclusion of AAD lipid values as covariates in the model (Table 3
,
statistical model 3) revealed that AAD total cholesterol
levels were predictive of total cholesterol response
(P=.0002); AAD LDL cholesterol levels were
predictive of LDL cholesterol response (P=.012);
AAD HDL cholesterol levels were predictive of HDL
cholesterol response (P<.0001); and AAD ln(TG)
values were marginally predictive of ln(TG) response
(P=.048). However, in this statistical model, apoE
genotype was still not predictive of diet response for any of
the lipid end points.
Our a priori model assumed that individual genotypes
within the E2 (E2/2, E2/3, E2/4) and E4 groups (E3/4, E4/4) responded
to diets in a similar manner. Failure of this assumption would lead to
higher variation in diet response within the E2 and E4 groups and
therefore might mask true genotype effects. Consequently, we
examined a statistical model in which the E2, E3, and E4 groups
contained only the genotypes of E2/3, E3/3, and E3/4,
respectively. When the narrower definition for inclusion into the apoE
genotype groups was used, the diet by genotype
interaction remained not significant (Table 3
, statistical model
4).
Finally, in our last model, we limited our comparisons to the two most
frequent genotypes, E3/3 and E3/4. This direct comparison
between these two genotypes also did not demonstrate a
significant diet by genotype interaction (Table 3
, statistical
model 5).
Power Analysis
An analysis of statistical power was performed, taking
into account the research protocol used (study design, recruitment
strategy, sample size, model assumptions, statistical algorithms) and
the estimated values of the variance components. In comparing the
genotypes with respect to LDL cholesterol
responsiveness to the Low-Sat diet, the research protocol provides a
90% chance of detecting any 0.33 mmol/L difference in
response among the three genotype groups. The result of this
power analysis suggests that either a rare event occurred in
the present study (diet by genotype interactions are very
large but were not detected), or the actual differences in LDL
cholesterol responsiveness among apoE genotype
groups are smaller than 0.33 mmol/L. Analogous results hold
for total cholesterol and other end point variables
considered.
| Discussion |
|---|
|
|
|---|
2 (112cys,
158cys),
3 (112cys, 158arg), and
4 (112arg, 158arg), profoundly affect
lipoprotein metabolism and consequently the fasting levels
of both total and LDL cholesterol.36 It was
therefore not unexpected that early work aimed at identifying the
genetic basis of diet responsiveness would focus on apoE gene
polymorphisms. Miettinen et al28 first reported that
apoE polymorphisms affect the magnitude of total
cholesterol and LDL cholesterol response to
changes in dietary cholesterol levels with individuals
possessing the
2 allele displaying smaller responses than those
possessing the
4 allele. While some investigators were able to
replicate these findings,26 28 others could
not.19 21 27 29 30
A number of diet studies have focused on the interaction between apoE
genotype and lipid response to combined changes in dietary
cholesterol levels and fatty acid content and composition
or to changes in fatty acid levels alone. These studies are summarized
in Table 4
. In approximately half the
reported studies, apoE genotype was shown to affect
significantly the magnitude of total plasma cholesterol and
LDL cholesterol response to a wide range of changes in
dietary total fat, saturated fatty acids, and cholesterol.
In studies showing a significant apoE interactive effect, individuals
possessing the
4 allele had the greatest response to dietary
changes compared with the remaining genotypes. For LDL
cholesterol, the variously defined "E4" groups
experienced, on average, a 74% greater response (range, 49% to 95%)
to reductions in saturated fat and cholesterol than that
observed in the remaining apoE genotype groups combined.
|
However, in an almost equal number of studies, apoE genotype
was not found to have any effect on diet responsiveness. From the
summary in Table 4
, studies that reported significant diet by apoE
genotype interactions tended to have studied predominantly
normocholesterolemic subjects and tended to examine
greater changes in total fat, saturated fat, and
cholesterol than studies where no significant interactions
were found. However, despite the differences in the magnitude of
dietary changes between these studies, the average decline in LDL
cholesterol observed in studies reporting a significant
diet by apoE genotype interaction (0.56 mmol/L) was
identical to that observed in studies where evidence for a diet by apoE
genotype interaction was not found. Interestingly, of the seven
studies reporting a significant apoE genotype effect on diet
response, three studies were conducted with only male participants,
while three others found significant effects in males but not females.
In the one study where an apoE genotype effect was found in
males and females,16 a later analysis of the same
data20 failed to reveal a significant diet by apoE
genotype interaction.
The DELTA study is the first well-controlled dietary investigation to employ a multicenter approach. The large number of subjects enrolled, coupled with the high level of dietary control and diet monitoring, provided an excellent opportunity to evaluate the impact of apoE genotype on lipid response to changes in the amounts of dietary saturated fatty acid consumed. The study population, by design, was diverse in both age and gender and included a substantial proportion of blacks. All six possible apoE genotypes were represented; however, their distribution differed slightly from predicted values. Our study population contained fewer than predicted E2/3 genotypes and more than predicted E3/4 genotypes. However, these differences were not significant and therefore were unlikely to have affected the outcome of our overall study.
In the present study, substantial evidence of a diet by apoE
genotype interaction was absent for all lipid, lipoprotein, and
apolipoprotein end points. In fact, the relative order of total and LDL
cholesterol response to the Step 1 diet across the apoE
genotype groups was opposite that previously reported in
studies showing a diet by apoE genotype interaction (see Table 4
). In our study, individuals with the E2 genotype group had
the greatest changes in total and LDL cholesterol response
to both the Step 1 and Low-Sat diets relative to both the E3 and E4
groups, although these differences were small and not significant.
The magnitude of changes in dietary total fat and saturated fat in the
present study may partially explain our negative findings. Changes
in total fat (5.7% of calories) and saturated fat (6.0% of calories)
between the AAD and the Step 1 diet are smaller than those used in
published studies demonstrating an effect of apoE genotype
(Table 4
). It is only in the comparison of the AAD with the Low-Sat
diet that differences in total fat (9.0% of calories) and saturated
fat (8.9% of calories) approach the range found in studies reporting
significant apoE genotype effects. On the Low-Sat diet, the E4
group did experience a 23% greater reduction in LDL
cholesterol relative to the E3 group; however, the
magnitude of this difference was well below the reported effects of E4
on LDL cholesterol response.
Given the evidence supporting a diet by apoE genotype interaction, we were somewhat surprised by our negative results. In particular, our results stand in marked contrast to a recently published retrospective analysis of three combined well-controlled dietary studies by Lopez-Miranda et al.14 In their study, after correction for BMI and age, males with the E3/4 genotype experienced an almost twofold greater decrease in LDL cholesterol than did males with the E3/3 genotype in response to reductions in both dietary saturated fatty acids and cholesterol. However, in the same analysis, genotype effects in females were not significant. As previously indicated, the findings of a gender effect by Lopez-Miranda are consistent with other published reports of significant diet by apoE genotype interactions in studies of only men or of significant diet by apoE genotype interactions in men but not women in studies including both genders. This prompted us to analyze our data taking gender into consideration. In men, LDL cholesterol reductions with the Low-Sat diet were 46% greater in the E4 group than in the E3 group. This contrasts with the findings in women in whom the LDL cholesterol response was only 18% greater in the E4 group than the E3 group. Thus, while we observed trends in our data similar to those previously published regarding the effects of E4 in men, these trends were only evident with the Low-Sat diet, were not as great as those previously published, and did not achieve statistical significance.
Additional analyses considered the effects of age, BMI,
baseline lipid levels, race, and genotype group definitions on
potential diet by apoE genotype interactions. However, these
additional analyses did not reconcile the differences in
results of the present study with those of other published reports
in that we still saw no effect of apoE genotype on the lipid
and lipoprotein response to diet (Table 3
).
Other differences between our study and those reporting significant apoE genotype-diet interactions warrant further consideration. In the present study, fasting lipid levels of subjects on the AAD approximated the 50th percentile for middle-aged Americans. Furthermore, in our study, differences in total and LDL cholesterol levels across apoE genotype groups while consuming the AAD were not marked or significant. This contrasts with other studies whose subjects were either moderately hypercholesterolemic14 15 16 31 and/or had significant and substantial differences in baseline lipid levels between the apoE genotype groups.14 16 25 It is possible that any diet by apoE genotype interaction is only manifest in subjects who are susceptible to hypercholesterolemia as a consequence of other genetic or environmental causes.
Finally, in the present study, only saturated fatty acid levels
were changed across diet. In the majority of other studies, there were
concomitant changes in both dietary fatty acids and
cholesterol (Table 4
). Only one study25 has
demonstrated a moderate effect of apoE genotype on LDL
cholesterol response in a design in which changes in
dietary fat levels were achieved (reductions in both saturated and
polyunsaturated fatty acids) without significant changes in dietary
cholesterol levels. Previous reports have shown that
cholesterol absorption is related to apoE
genotype39 and may account for the reported
differences in apoE genotype response to isolated changes in
dietary cholesterol. If the primary interaction is between
apoE genotype and dietary cholesterol, then the
negative findings in our study would not be unexpected, since dietary
cholesterol was held constant.
In conclusion, the present study has shown that every apoE genotype group responded to changes in dietary saturated fat with significant reductions in total and LDL cholesterol. We have previously reported41 similarly significant reductions in total and LDL cholesterol in various subgroups of this same study population when categorized by age, gender, menopausal status, and race. Therefore, at present, we have not identified any significant population subgroup that does not, on average, experience beneficial changes in both total and LDL cholesterol levels in response to reductions in dietary saturated fat.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
| Appendix 1 |
|---|
|
|
|---|
Columbia University
Henry N. Ginsberg, MD, Principal Investigator; Rajasekhar
Ramakrishnan, ScD; Wahida Karmally, MS, RD; Lars Berglund, MD; Maliha
Siddiqui, MS, RD; Niem-Tzu Chen, MS; Steve Holleran, BS; Colleen
Johnson, RD; Roberta Holeman; Karen Chirgwin; Kellye Stennett; Lencey
Ganga; Tajudeen T. Towalawi, MBA; Minnie Myers, BS; Colleen Ngai, BS;
Nelson Fontenez, BS; Jeff Jones, BS; Carmen Rodriguez; Norma
Useche.
Pennington Biomedical Research Center
Michael Lefevre, PhD and Paul S. Roheim, MD, Co-Principal
Investigators; Donna H. Ryan, MD; Marlene M. Windhauser, PhD, RD;
Catherine M. Champagne, PhD, RD; Donald Williamson, PhD, Richard
Tulley, PhD; Ricky Brock, RN; Deonne Bodin, BS, MT; Betty Kennedy, MPA;
Michelle Barkate, MS, RD; Elizabeth Foust, BS; Deshoin York, BS.
Pennsylvania State University
Penny Kris-Etherton, PhD, Principal Investigator; Satya S.
Jonnalagadda, PhD; Janice Derr, PhD; Abir Farhat-Wood, MS; Vikkie A.
Mustad, MS; Kate Meaker, MS; Edward Mills, PhD; Mary-Ann Tilley, MS,
RD; Helen Smiciklas-Wright, PhD; Madeline Sigman-Grant, PhD, RD;
Jean-Xavier Guinard, PhD; Pamela Sechevich, MS; C. Channa Reddy, PhD;
Andrea M. Mastro, PhD; Allen Cooper, MD.
University of Minnesota
Patricia Elmer, PhD, Principal Investigator; Aaron Folsom, MD;
Nancy Van Heel, MS, RD; Christine Wold, RD; Kay Fritz, MA, RD; Joanne
Slavin, PhD; David Jacobs, PhD.
University of North Carolina at Chapel Hill
Barbara H. Dennis, PhD, Principal Investigator; Paul Stewart,
PhD; C.E. Davis, PhD; James Hosking, PhD; Nancy Anderson, MSPH; Susan
Blackwell, BS; Lynn Martin, MS; Hope Bryan, MS; W. Brian Stewart, BS;
Jeffrey Abolafia, MA; Malachy Foley, BS; Conroy Zien, BA; Szu-Yun Leu,
MS; Marston Youngblood, MPH; Thomas Goodwin, MAT; Monica Miles;
Jennifer Wehbie.
Mary Imogene Bassett Research Institute
Tom Pearson, MD, PhD; Roberta Reed, PhD.
University of Vermont
Russell Tracy, PhD; Elaine Cornell, BS.
Virginia Polytechnic and State University
Kent K Stewart, PhD; Katherine M. Phillips, PhD.
Southern University
Bernestine B. McGee, PhD; RD; Brenda Williams, BS.
Beltsville Agricultural Research Center
Gary R. Beecher, PhD; Joanne M. Holden, MS; Carol S. Davis,
BS.
National Heart, Lung, and Blood Institute
Abby G Ershow, ScD; David J. Gordon, MD; Michael Proschan, PhD;
Basil M. Rifkind, MD, FRCP.
Received April 10, 1997; accepted July 15, 1997.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Saito, M. Eto, H. Nitta, Y. Kanda, M. Shigeto, K. Nakayama, K. Tawaramoto, F. Kawasaki, S. Kamei, K. Kohara, et al. Effect of Apolipoprotein E4 Allele on Plasma LDL Cholesterol Response to Diet Therapy in Type 2 Diabetic Patients Diabetes Care, June 1, 2004; 27(6): 1276 - 1280. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. F Masson, G. McNeill, and A. Avenell Genetic variation and the lipid response to dietary intervention: a systematic review Am. J. Clinical Nutrition, May 1, 2003; 77(5): 1098 - 1111. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Lehtimaki, P. Dastidar, H. Jokela, T. Koivula, S. Lehtinen, C. Ehnholm, and R. Punnonen Effect of Long-Term Hormone Replacement Therapy on Atherosclerosis Progression in Postmenopausal Women Relates to Functional Apolipoprotein E Genotype J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4147 - 4153. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Eichner, S. T. Dunn, G. Perveen, D. M. Thompson, K. E. Stewart, and B. C. Stroehla Apolipoprotein E Polymorphism and Cardiovascular Disease: A HuGE Review Am. J. Epidemiol., March 15, 2002; 155(6): 487 - 495. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Corella, K. Tucker, C. Lahoz, O. Coltell, L A. Cupples, P. W. Wilson, E. J Schaefer, and J. M Ordovas Alcohol drinking determines the effect of the APOE locus on LDL-cholesterol concentrations in men: the Framingham Offspring Study Am. J. Clinical Nutrition, April 1, 2001; 73(4): 736 - 745. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. T Erkkila, E. S Sarkkinen, V. Lindi, S. Lehto, M. Laakso, and M. I. Uusitupa APOE polymorphism and the hypertriglyceridemic effect of dietary sucrose Am. J. Clinical Nutrition, April 1, 2001; 73(4): 746 - 752. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Ballantyne, J. A. Herd, E. A. Stein, L. L. Ferlic, J. K. Dunn, A. M. Gotto Jr., and A. J. Marian Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1572 - 1578. [Abstract] [Full Text] [PDF] |
||||
![]() |
|